Less-favorable CLL prognostic markers such as del(17p) or TP53 dysfunction do not lead to long-term remissions with standard chemoimmunotherapy and patients with these disease features are best treated with novel agents [14]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.